Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
Portfolio Pulse from Vandana Singh
Mizuho Securities initiated coverage on Vaxcyte Inc (PCVX), a vaccine company, with a Buy rating and a price target of $69. Vaxcyte's lead asset VAX-24, targeting pneumococcal disease, is set to enter Phase 3 in 2024. Vaxcyte's technology could disrupt Pfizer's (PFE) long-standing near monopoly in pneumococcal vaccines. Vaxcyte's vaccines, VAX-24 and VAX-31, cover more serotypes than Pfizer's current vaccines, potentially offering broader disease prevention.
December 07, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer Inc's long-standing near monopoly in pneumococcal vaccines could be challenged by Vaxcyte's advanced serotype coverage technology.
The potential disruption of Pfizer's pneumococcal vaccine monopoly by Vaxcyte's new technology could negatively impact Pfizer's vaccine revenue in the long term. In the short term, this news may cause concern among investors and could put downward pressure on Pfizer's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Vaxcyte Inc received a Buy rating from Mizuho Securities with a price target of $69, indicating a positive outlook for its pneumococcal vaccines VAX-24 and VAX-31.
The initiation of coverage by Mizuho Securities with a Buy rating and a high price target suggests strong confidence in Vaxcyte's technology and market potential. This positive analyst coverage is likely to attract investor interest and could lead to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100